Flow Cytometry Instruments and Reagents
Embecta Corporation is a standalone public company focused on diabetes care. Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. Surgical efficiency, patient safety and outcomes, procedural cost management
Health and safety issues
BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
- In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.
- BD announced that it notified customers about the recall by letter and has been working with the U.S.
- In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion.
Use a variety of training courses for instruments and applications to take full advantage of the capabilities of BD products. Explore our webinar series spanning a broad range of topics and in-depth reviews by senior scientists, professionals and clinicians. Houses many of our pre-designed multicolor flow cytometry panels. Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research. These subtle changes would not have been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform.
The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research. Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and https://betjilibangladesh.com safety law that had resulted in two employees having partial finger amputations.
In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.